Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property
Tickers XBIO
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers XBIO
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
From Xenetic Biosciences, Inc.
Via AccessWire
Tickers XBIO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.